Clinical trial · Interventional
Fufang E'Jiao Jiang Intervening Cancer-related Fatigue
The Study on the Clinical Value of Fufang E'Jiao Jiang Intervening Cancer-related Fatigue (Deficiency of Qi and Blood)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
With the therapeutic tool of carcinoma increasing, life span extending, the solicitude for the patients'quality of life appear more important. Cancer-related fatigue (CRF) is one of the most prevalent and debilitating symptoms experienced by people with cancer. It can persist for months or years after cancer therapy is completed and has a negative impact on all areas of function. Meaningful evidence-based treatment options for CRF are extremely limited and finding safe, inexpensive, and effective interventions for managing this distressing symptom are urgently needed. Our previous clinical experience have shown that traditional Chinese medicine（TCM） had a great effect on improving CRF, Several studies proven that its'mechanism were related to the regulation of immune function and endocrine hormones. Fufang E'Jiao Jiang (FFEJJICRF) is a commonly-used Chinese patent medicine and successfully marketed in China for many years, which are effective in improvement for TCM symptoms of deficiency with qi and blood. This proposal will investigate the effects of FFEJJICRF on CRF among non-small cell lung cancer, colorectal cancer, and gastric cancer, so as to find a new way for curing it in clinical.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer-related Fatigue | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fufang E'Jiao Jiang | Drug | — | UNRESOLVED |
| placebo containing low-dose fufang E'Jiao Jiang | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Treatment group
- description
- Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21days each cycle, and use 2 cycles
- interventionNames
- Drug: Fufang E'Jiao Jiang
- type
- PLACEBO_COMPARATOR
- label
- control group
- description
- Placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
- interventionNames
- Drug: placebo containing low-dose fufang E'Jiao Jiang
Primary outcomes (1)
- measure
- Fatigue degree with the Piper fatigue scale (Piper)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. The age of patients between 18 and 75，gender not limited. 2. Patients that pathologically diagnosed with colorectal cancer, non-small cell lung cancer (NSCLC) or gastric cancer. 3. The patients' TNM stage of NSCLC is IIIB-IV, colorectal cancer is IV, and gastric cancer is IV, in addition all of them should be with tumors that can not be radically resected. 4. If patients have not received chemotherapy, they should be evaluated that tumor will not progress within 30 days, and their bodies can tolerate intravenous targeted therapy. 5. Patients who meet the diagnostic criterion for cancer related fatigue with deficiency of qi and blood. 6. The expected survival period is more than 3 months. 7. Fatigue score evaluated by visual analogue fatigue scale isn't lower than 4, and Karnofsky scale score isn't lower than 60. 8. Good compliance and agreeable to sign an informed consent before test. 9. Subjects agree not to participate in other intervention studies during test. Exclusion Criteria: 1. Those who need immunotherapy or radiotherapy during the test. 2. Those who have significant trauma injuries in the past one month. 3. Those who have severe bleeding or systemic infection diseases that had not been completely controlled. 4. Those who have tangible proofs of marrow or central nervous system metastasis. 5. Those who have received erythropoietin or blood transfusion within 1 month before test. 6. Those who have hypersplenism, hyperthyroidism, desmosis, tuberculosis and other diseases that have not been completely controlled. 7. Those who complicated with serious diseases such as cardiovascular or cerebrovascular system diseases, active hepatitis, disfunction of liver or kidney. 8. Those who are known or suspected to be allergic to test drugs. 9. Those who have eaten EJiao products in the past 2 weeks. 10. Those who have occurred Ileus. 11. Those suffering from severe malabsorption or other diseases that affect gastrointestinal absorption. 12. Those who cannot understand, read and fill in the self-rating scale due to their level of knowledge or intelligence. 13. Those who may happen any unstable conditions or conditions that endanger the patient's safety or compliance, for example the spirits. 14. Those who have been diagnosed with other malignant tumors (except fully treated cervix and skin carcinoma in situ, or other tumors that have been surgically cured and not recurred for at least 5 years) . 15. Those who participated in other therapeutic clinical trials within 30 days. 16. Pregnant or nursing women, or childbearing female that are inadequate contraception. 17. Those who are inappropriate to participate in the study determined by investigators.
References
Publications (1)
- DERIVEDSong Z, Sun LY, Gu SS, Zhu XS, Lai HZ, Lu F, Cui N, Li QY, Wu Y, Xu Y. Exploring the Safety, Effectiveness, and Cost-Effectiveness of a Chinese Patent Medicine (Fufang E'jiao Syrup) for Alleviating Cancer-Related Fatigue: A Protocol for a Randomized, Double-Blinded, Placebo-Controlled, Multicenter Trial. Integr Cancer Ther. 2021 Jan-Dec;20:15347354211002919. doi: 10.1177/15347354211002919. PMID 33834863